Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
22
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Budd Haeberlein Samantha L. | Director | 14 | $20.5K | $0 | 2025-08-05 |
| Gray David L. F. | Chief Science Officer | 8 | $0 | $0 | 2025-08-05 |
| Kaufmann Petra | Chief Medical Officer | 4 | $0 | $0 | 2025-08-05 |
| Koenig Gerhard | Director | 19 | $0 | $0 | 2025-08-05 |
| Vitorovic Stefan | Director | 18 | $23.45M | $0 | 2025-08-05 |
| Atlas Venture Opportunity Fund I, L.P. | 10% Owner | 7 | $7.49M | $0 | 2025-08-05 |
| Ziolkowski Jennifer Lynn | Chief Financial Officer | 18 | $15.1K | $0 | 2025-08-05 |
| Bruhn Suzanne Louise | Director | 20 | $0 | $0 | 2025-08-05 |
| Booth Bruce | Director | 31 | $7.49M | $0 | 2025-08-05 |
| Blanchard Cheryl R | Director | 24 | $0 | $0 | 2025-08-05 |
| Thistle Mary | Director | 16 | $0 | $0 | 2025-08-05 |
| Magovcevic-Liebisch Ivana | President and CEO | 23 | $61.8K | $0 | 2025-08-05 |
| Verni Christopher | General Counsel | 8 | $15.1K | $0 | 2024-05-03 |
| Silber Christopher | Chief Medical Officer | 1 | $0 | $0 | 2023-08-07 |
| Thackaberry Evan | SVP, Head of Early Development | 3 | $6.0K | $0 | 2023-03-01 |
| Papapetropoulos Spyros | Chief Medical Officer | 5 | $13.6K | $4.2K | 2022-11-18 |
| Thorp Clay | Director | 7 | $3.84M | $0 | 2022-05-17 |
| AMGEN INC | 10% Owner | 2 | $0 | $0 | 2022-01-11 |
| Northpond Ventures, LP | 10% Owner | 5 | $4.97M | $0 | 2022-01-11 |
| Vida Ventures GP III, L.L.C. | 10% Owner | 6 | $23.45M | $0 | 2022-01-11 |
| Alexandria Venture Investments, LLC | 10% Owner | 3 | $0 | $0 | 2022-01-11 |
| Cormorant Global Healthcare Master Fund, LP | Other | 2 | $0 | $0 | 2022-01-11 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Koenig Gerhard | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 18,068 | — | $0 | 0 | SEC↗ |
| Koenig Gerhard | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 13,928 | — | $0 | 0 | SEC↗ |
| Koenig Gerhard | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 4,351 | — | $0 | 0 | SEC↗ |
| Koenig Gerhard | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 36,690 | — | $0 | 0 | SEC↗ |
| Koenig Gerhard | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 6,954 | — | $0 | 0 | SEC↗ |
| Koenig Gerhard | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 18,029 | — | $0 | 0 | SEC↗ |
| Koenig Gerhard | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 12,155 | — | $0 | 0 | SEC↗ |
| Blanchard Cheryl R | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 24,761 | — | $0 | 0 | SEC↗ |
| Blanchard Cheryl R | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 36,690 | — | $0 | 0 | SEC↗ |
| Blanchard Cheryl R | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 5,017 | — | $0 | 0 | SEC↗ |
| Blanchard Cheryl R | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 13,928 | — | $0 | 0 | SEC↗ |
| Blanchard Cheryl R | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 18,068 | — | $0 | 0 | SEC↗ |
| Blanchard Cheryl R | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 6,432 | — | $0 | 0 | SEC↗ |
| Blanchard Cheryl R | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 12,155 | — | $0 | 0 | SEC↗ |
| Blanchard Cheryl R | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 24,984 | — | $0 | 0 | SEC↗ |
| Gray David L. F. | Chief Science Officer | D To issuer deriv | 2025-08-05 | 2025-08-05 | 125,000 | — | $0 | 0 | SEC↗ |
| Gray David L. F. | Chief Science Officer | D To issuer deriv | 2025-08-05 | 2025-08-05 | 267,000 | — | $0 | 0 | SEC↗ |
| Gray David L. F. | Chief Science Officer | D To issuer deriv | 2025-08-05 | 2025-08-05 | 125,000 | — | $0 | 0 | SEC↗ |
| Bruhn Suzanne Louise | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 33,875 | — | $0 | 0 | SEC↗ |
| Bruhn Suzanne Louise | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 18,068 | — | $0 | 0 | SEC↗ |
| Bruhn Suzanne Louise | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 24,073 | — | $0 | 0 | SEC↗ |
| Bruhn Suzanne Louise | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 6,235 | — | $0 | 0 | SEC↗ |
| Bruhn Suzanne Louise | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 24,310 | — | $0 | 0 | SEC↗ |
| Bruhn Suzanne Louise | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 13,928 | — | $0 | 0 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | D To issuer deriv | 2025-08-05 | 2025-08-05 | 282,000 | — | $0 | 0 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | D To issuer deriv | 2025-08-05 | 2025-08-05 | 43,271 | — | $0 | 0 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | D To issuer deriv | 2025-08-05 | 2025-08-05 | 405,494 | — | $0 | 0 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | D To issuer deriv | 2025-08-05 | 2025-08-05 | 210,629 | — | $0 | 0 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | D To issuer deriv | 2025-08-05 | 2025-08-05 | 369,351 | — | $0 | 0 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | D To issuer deriv | 2025-08-05 | 2025-08-05 | 485,000 | — | $0 | 0 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | D To issuer deriv | 2025-08-05 | 2025-08-05 | 370,000 | — | $0 | 0 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | D To issuer deriv | 2025-08-05 | 2025-08-05 | 463,000 | — | $0 | 0 | SEC↗ |
| Vitorovic Stefan | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 18,068 | — | $0 | 0 | SEC↗ |
| Vitorovic Stefan | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 13,928 | — | $0 | 0 | SEC↗ |
| Vitorovic Stefan | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 12,155 | — | $0 | 0 | SEC↗ |
| Booth Bruce | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 7,577 | — | $0 | 0 | SEC↗ |
| Booth Bruce | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 12,155 | — | $0 | 0 | SEC↗ |
| Booth Bruce | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 9,713 | — | $0 | 0 | SEC↗ |
| Booth Bruce | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 13,928 | — | $0 | 0 | SEC↗ |
| Booth Bruce | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 34,612 | — | $0 | 0 | SEC↗ |
| Booth Bruce | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 48,393 | — | $0 | 0 | SEC↗ |
| Booth Bruce | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 18,068 | — | $0 | 0 | SEC↗ |
| Ziolkowski Jennifer Lynn | Chief Financial Officer | D To issuer deriv | 2025-08-05 | 2025-08-05 | 156,000 | — | $0 | 0 | SEC↗ |
| Ziolkowski Jennifer Lynn | Chief Financial Officer | D To issuer deriv | 2025-08-05 | 2025-08-05 | 135,000 | — | $0 | 0 | SEC↗ |
| Ziolkowski Jennifer Lynn | Chief Financial Officer | D To issuer deriv | 2025-08-05 | 2025-08-05 | 110,000 | — | $0 | 0 | SEC↗ |
| Ziolkowski Jennifer Lynn | Chief Financial Officer | D To issuer deriv | 2025-08-05 | 2025-08-05 | 49,968 | — | $0 | 0 | SEC↗ |
| Ziolkowski Jennifer Lynn | Chief Financial Officer | D To issuer deriv | 2025-08-05 | 2025-08-05 | 119,923 | — | $0 | 0 | SEC↗ |
| Ziolkowski Jennifer Lynn | Chief Financial Officer | D To issuer deriv | 2025-08-05 | 2025-08-05 | 96,051 | — | $0 | 0 | SEC↗ |
| Ziolkowski Jennifer Lynn | Chief Financial Officer | D To issuer deriv | 2025-08-05 | 2025-08-05 | 21,635 | — | $0 | 0 | SEC↗ |
| Ziolkowski Jennifer Lynn | Chief Financial Officer | D To issuer deriv | 2025-08-05 | 2025-08-05 | 156,000 | — | $0 | 0 | SEC↗ |
| Budd Haeberlein Samantha L. | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 13,928 | — | $0 | 0 | SEC↗ |
| Budd Haeberlein Samantha L. | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 18,068 | — | $0 | 0 | SEC↗ |
| Budd Haeberlein Samantha L. | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 30,694 | — | $0 | 0 | SEC↗ |
| Kaufmann Petra | Chief Medical Officer | D To issuer deriv | 2025-08-05 | 2025-08-05 | 330,000 | — | $0 | 0 | SEC↗ |
| Kaufmann Petra | Chief Medical Officer | D To issuer deriv | 2025-08-05 | 2025-08-05 | 144,000 | — | $0 | 0 | SEC↗ |
| Thistle Mary | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 24,309 | — | $0 | 0 | SEC↗ |
| Thistle Mary | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 18,068 | — | $0 | 0 | SEC↗ |
| Thistle Mary | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 13,928 | — | $0 | 0 | SEC↗ |
| Thistle Mary | Director | D To issuer deriv | 2025-08-05 | 2025-08-05 | 12,155 | — | $0 | 0 | SEC↗ |
| Koenig Gerhard | Director | D To issuer | 2025-08-05 | 2025-08-05 | 5,000 | — | $0 | 0 | SEC↗ |
| Blanchard Cheryl R | Director | D To issuer | 2025-08-05 | 2025-08-05 | 5,000 | — | $0 | 0 | SEC↗ |
| Bruhn Suzanne Louise | Director | D To issuer | 2025-08-05 | 2025-08-05 | 5,000 | — | $0 | 0 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | D To issuer | 2025-08-05 | 2025-08-05 | 222,687 | — | $0 | 0 | SEC↗ |
| Vitorovic Stefan | Director | D To issuer | 2025-08-05 | 2025-08-05 | 5,000 | — | $0 | 0 | SEC↗ |
| Booth Bruce | Director | D To issuer | 2025-08-05 | 2025-08-05 | 5,000 | — | $0 | 0 | SEC↗ |
| Booth Bruce | Director | D To issuer | 2025-08-05 | 2025-08-05 | 1,027,978 | — | $0 | 0 | SEC↗ |
| Booth Bruce | Director | D To issuer | 2025-08-05 | 2025-08-05 | 4,808,896 | — | $0 | 0 | SEC↗ |
| Ziolkowski Jennifer Lynn | Chief Financial Officer | D To issuer | 2025-08-05 | 2025-08-05 | 4,000 | — | $0 | 0 | SEC↗ |
| Budd Haeberlein Samantha L. | Director | D To issuer | 2025-08-05 | 2025-08-05 | 12,000 | — | $0 | 0 | SEC↗ |
| Budd Haeberlein Samantha L. | Director | D To issuer | 2025-08-05 | 2025-08-05 | 5,000 | — | $0 | 0 | SEC↗ |
| Thistle Mary | Director | D To issuer | 2025-08-05 | 2025-08-05 | 5,000 | — | $0 | 0 | SEC↗ |
| Atlas Venture Opportunity Fund | 10% Owner | D To issuer | 2025-08-05 | 2025-08-07 | 4,808,896 | — | $0 | 0 | SEC↗ |
| Atlas Venture Opportunity Fund | 10% Owner | D To issuer | 2025-08-05 | 2025-08-07 | 1,027,978 | — | $0 | 0 | SEC↗ |
| Thistle Mary | Director | A Award | 2025-05-22 | 2025-05-23 | 5,000 | — | $0 | 5,000 | SEC↗ |
| Blanchard Cheryl R | Director | A Award | 2025-05-22 | 2025-05-23 | 5,000 | — | $0 | 5,000 | SEC↗ |
| Budd Haeberlein Samantha L. | Director | A Award | 2025-05-22 | 2025-05-23 | 5,000 | — | $0 | 17,000 | SEC↗ |
| Koenig Gerhard | Director | A Award | 2025-05-22 | 2025-05-23 | 5,000 | — | $0 | 5,000 | SEC↗ |
| Bruhn Suzanne Louise | Director | A Award | 2025-05-22 | 2025-05-23 | 5,000 | — | $0 | 5,000 | SEC↗ |
| Vitorovic Stefan | Director | A Award | 2025-05-22 | 2025-05-23 | 5,000 | — | $0 | 5,000 | SEC↗ |
| Booth Bruce | Director | A Award | 2025-05-22 | 2025-05-23 | 5,000 | — | $0 | 5,000 | SEC↗ |
| Booth Bruce | Director | A Award deriv | 2025-03-03 | 2025-03-04 | 48,393 | — | $0 | 48,393 | SEC↗ |
| Gray David L. F. | Chief Science Officer | A Award deriv | 2025-03-03 | 2025-03-04 | 125,000 | — | $0 | 125,000 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | A Award deriv | 2025-03-03 | 2025-03-04 | 485,000 | — | $0 | 485,000 | SEC↗ |
| Bruhn Suzanne Louise | Director | A Award deriv | 2025-03-03 | 2025-03-04 | 33,875 | — | $0 | 33,875 | SEC↗ |
| Ziolkowski Jennifer Lynn | Chief Financial Officer | A Award deriv | 2025-03-03 | 2025-03-04 | 156,000 | — | $0 | 156,000 | SEC↗ |
| Kaufmann Petra | Chief Medical Officer | A Award deriv | 2025-03-03 | 2025-03-04 | 144,000 | — | $0 | 144,000 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | P Buy | 2024-12-19 | 2024-12-19 | 5,000 | $1.68 | $8.4K | 222,687 | SEC↗ |
| Budd Haeberlein Samantha L. | Director | P Buy | 2024-12-19 | 2024-12-19 | 12,000 | $1.71 | $20.5K | 12,000 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | P Buy | 2024-12-18 | 2024-12-18 | 5,000 | $1.67 | $8.3K | 217,687 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | P Buy | 2024-12-05 | 2024-12-05 | 5,000 | $2.34 | $11.7K | 212,687 | SEC↗ |
| Blanchard Cheryl R | Director | A Award deriv | 2024-06-05 | 2024-06-07 | 18,068 | — | $0 | 18,068 | SEC↗ |
| Budd Haeberlein Samantha L. | Director | A Award deriv | 2024-06-05 | 2024-06-07 | 18,068 | — | $0 | 18,068 | SEC↗ |
| Booth Bruce | Director | A Award deriv | 2024-06-05 | 2024-06-07 | 18,068 | — | $0 | 18,068 | SEC↗ |
| Koenig Gerhard | Director | A Award deriv | 2024-06-05 | 2024-06-07 | 18,068 | — | $0 | 18,068 | SEC↗ |
| Bruhn Suzanne Louise | Director | A Award deriv | 2024-06-05 | 2024-06-07 | 18,068 | — | $0 | 18,068 | SEC↗ |
| Thistle Mary | Director | A Award deriv | 2024-06-05 | 2024-06-07 | 18,068 | — | $0 | 18,068 | SEC↗ |
| Vitorovic Stefan | Director | A Award deriv | 2024-06-05 | 2024-06-07 | 18,068 | — | $0 | 18,068 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | D To issuer deriv | 2024-05-03 | 2024-05-07 | 282,000 | — | $0 | 0 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | A Award deriv | 2024-05-03 | 2024-05-07 | 282,000 | — | $0 | 282,000 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | D To issuer deriv | 2024-05-03 | 2024-05-07 | 370,000 | — | $0 | 0 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | A Award deriv | 2024-05-03 | 2024-05-07 | 370,000 | — | $0 | 370,000 | SEC↗ |
| Ziolkowski Jennifer Lynn | Chief Financial Officer | A Award deriv | 2024-05-03 | 2024-05-07 | 135,000 | — | $0 | 135,000 | SEC↗ |
| Ziolkowski Jennifer Lynn | Chief Financial Officer | D To issuer deriv | 2024-05-03 | 2024-05-07 | 135,000 | — | $0 | 0 | SEC↗ |
| Ziolkowski Jennifer Lynn | Chief Financial Officer | D To issuer deriv | 2024-05-03 | 2024-05-07 | 110,000 | — | $0 | 0 | SEC↗ |
| Ziolkowski Jennifer Lynn | Chief Financial Officer | A Award deriv | 2024-05-03 | 2024-05-07 | 110,000 | — | $0 | 110,000 | SEC↗ |
| Koenig Gerhard | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 4,351 | $9.63 | $41.9K | 0 | SEC↗ |
| Koenig Gerhard | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 4,351 | — | $0 | 4,351 | SEC↗ |
| Koenig Gerhard | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 13,928 | — | $0 | 13,928 | SEC↗ |
| Koenig Gerhard | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 13,928 | — | $0 | 0 | SEC↗ |
| Koenig Gerhard | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 12,155 | — | $0 | 0 | SEC↗ |
| Koenig Gerhard | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 12,155 | — | $0 | 12,155 | SEC↗ |
| Blanchard Cheryl R | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 5,017 | $9.63 | $48.3K | 0 | SEC↗ |
| Blanchard Cheryl R | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 5,017 | — | $0 | 5,017 | SEC↗ |
| Blanchard Cheryl R | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 12,155 | — | $0 | 0 | SEC↗ |
| Blanchard Cheryl R | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 12,155 | — | $0 | 12,155 | SEC↗ |
| Blanchard Cheryl R | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 6,432 | $7.62 | $49.0K | 0 | SEC↗ |
| Blanchard Cheryl R | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 6,432 | — | $0 | 6,432 | SEC↗ |
| Blanchard Cheryl R | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 13,928 | — | $0 | 0 | SEC↗ |
| Blanchard Cheryl R | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 13,928 | — | $0 | 13,928 | SEC↗ |
| Thistle Mary | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 24,309 | — | $0 | 0 | SEC↗ |
| Thistle Mary | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 24,309 | — | $0 | 24,309 | SEC↗ |
| Thistle Mary | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 12,155 | — | $0 | 0 | SEC↗ |
| Thistle Mary | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 12,155 | — | $0 | 12,155 | SEC↗ |
| Thistle Mary | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 13,928 | — | $0 | 13,928 | SEC↗ |
| Thistle Mary | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 13,928 | — | $0 | 0 | SEC↗ |
| Bruhn Suzanne Louise | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 6,235 | $7.62 | $47.5K | 0 | SEC↗ |
| Bruhn Suzanne Louise | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 24,310 | — | $0 | 0 | SEC↗ |
| Bruhn Suzanne Louise | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 24,310 | — | $0 | 24,310 | SEC↗ |
| Bruhn Suzanne Louise | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 6,235 | — | $0 | 6,235 | SEC↗ |
| Bruhn Suzanne Louise | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 13,928 | — | $0 | 0 | SEC↗ |
| Bruhn Suzanne Louise | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 13,928 | — | $0 | 13,928 | SEC↗ |
| Vitorovic Stefan | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 13,928 | — | $0 | 13,928 | SEC↗ |
| Vitorovic Stefan | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 12,155 | — | $0 | 0 | SEC↗ |
| Vitorovic Stefan | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 12,155 | — | $0 | 12,155 | SEC↗ |
| Vitorovic Stefan | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 13,928 | — | $0 | 0 | SEC↗ |
| Budd Haeberlein Samantha L. | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 13,928 | — | $0 | 0 | SEC↗ |
| Budd Haeberlein Samantha L. | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 30,694 | — | $0 | 0 | SEC↗ |
| Budd Haeberlein Samantha L. | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 30,694 | — | $0 | 30,694 | SEC↗ |
| Budd Haeberlein Samantha L. | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 13,928 | — | $0 | 13,928 | SEC↗ |
| Verni Christopher | General Counsel | D To issuer deriv | 2024-05-03 | 2024-05-07 | 85,000 | — | $0 | 0 | SEC↗ |
| Verni Christopher | General Counsel | A Award deriv | 2024-05-03 | 2024-05-07 | 85,000 | — | $0 | 85,000 | SEC↗ |
| Verni Christopher | General Counsel | A Award deriv | 2024-05-03 | 2024-05-07 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Verni Christopher | General Counsel | D To issuer deriv | 2024-05-03 | 2024-05-07 | 150,000 | — | $0 | 0 | SEC↗ |
| Gray David L. F. | Chief Science Officer | D To issuer deriv | 2024-05-03 | 2024-05-07 | 267,000 | — | $0 | 0 | SEC↗ |
| Gray David L. F. | Chief Science Officer | A Award deriv | 2024-05-03 | 2024-05-07 | 267,000 | — | $0 | 267,000 | SEC↗ |
| Booth Bruce | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 9,713 | — | $0 | 9,713 | SEC↗ |
| Booth Bruce | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 13,928 | — | $0 | 13,928 | SEC↗ |
| Booth Bruce | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 13,928 | — | $0 | 0 | SEC↗ |
| Booth Bruce | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 7,577 | $9.63 | $73.0K | 0 | SEC↗ |
| Booth Bruce | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 12,155 | — | $0 | 0 | SEC↗ |
| Booth Bruce | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 12,155 | — | $0 | 12,155 | SEC↗ |
| Booth Bruce | Director | D To issuer deriv | 2024-05-03 | 2024-05-07 | 9,713 | $7.62 | $74.0K | 0 | SEC↗ |
| Booth Bruce | Director | A Award deriv | 2024-05-03 | 2024-05-07 | 7,577 | — | $0 | 7,577 | SEC↗ |
| Kaufmann Petra | Chief Medical Officer | A Award deriv | 2024-03-18 | 2024-03-20 | 330,000 | — | $0 | 330,000 | SEC↗ |
| Gray David L. F. | Chief Science Officer | A Award deriv | 2024-03-01 | 2024-03-01 | 125,000 | — | $0 | 125,000 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | A Award deriv | 2024-03-01 | 2024-03-01 | 463,000 | — | $0 | 463,000 | SEC↗ |
| Ziolkowski Jennifer Lynn | Chief Financial Officer | A Award deriv | 2024-03-01 | 2024-03-01 | 156,000 | — | $0 | 156,000 | SEC↗ |
| Verni Christopher | General Counsel | A Award deriv | 2024-03-01 | 2024-03-01 | 116,000 | — | $0 | 116,000 | SEC↗ |
| Blanchard Cheryl R | Director | A Award deriv | 2024-03-01 | 2024-03-05 | 24,761 | — | $0 | 24,761 | SEC↗ |
| Bruhn Suzanne Louise | Director | A Award deriv | 2024-03-01 | 2024-03-05 | 24,073 | — | $0 | 24,073 | SEC↗ |
| Booth Bruce | Director | A Award deriv | 2024-03-01 | 2024-03-05 | 34,612 | — | $0 | 34,612 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | P Buy | 2023-11-20 | 2023-11-20 | 4,000 | $3.75 | $15.0K | 207,687 | SEC↗ |
| Silber Christopher | Chief Medical Officer | A Award deriv | 2023-08-07 | 2023-08-07 | 330,000 | — | $0 | 330,000 | SEC↗ |
| Budd Haeberlein Samantha L. | Director | A Award deriv | 2023-06-07 | 2023-06-09 | 13,928 | — | $0 | 13,928 | SEC↗ |
| Booth Bruce | Director | A Award deriv | 2023-06-07 | 2023-06-09 | 13,928 | — | $0 | 13,928 | SEC↗ |
| Vitorovic Stefan | Director | A Award deriv | 2023-06-07 | 2023-06-09 | 13,928 | — | $0 | 13,928 | SEC↗ |
| Blanchard Cheryl R | Director | A Award deriv | 2023-06-07 | 2023-06-09 | 13,928 | — | $0 | 13,928 | SEC↗ |
| Koenig Gerhard | Director | A Award deriv | 2023-06-07 | 2023-06-09 | 13,928 | — | $0 | 13,928 | SEC↗ |
| Thistle Mary | Director | A Award deriv | 2023-06-07 | 2023-06-09 | 13,928 | — | $0 | 13,928 | SEC↗ |
| Bruhn Suzanne Louise | Director | A Award deriv | 2023-06-07 | 2023-06-09 | 13,928 | — | $0 | 13,928 | SEC↗ |
| Budd Haeberlein Samantha L. | Director | A Award deriv | 2023-05-08 | 2023-05-09 | 30,694 | — | $0 | 30,694 | SEC↗ |
| Ziolkowski Jennifer Lynn | Chief Financial Officer | A Award deriv | 2023-03-01 | 2023-03-03 | 135,000 | — | $0 | 135,000 | SEC↗ |
| Blanchard Cheryl R | Director | A Award deriv | 2023-03-01 | 2023-03-03 | 6,432 | $7.62 | $49.0K | 6,432 | SEC↗ |
| Thackaberry Evan | SVP, Head of Early Developme | A Award deriv | 2023-03-01 | 2023-03-03 | 65,000 | — | $0 | 65,000 | SEC↗ |
| Verni Christopher | General Counsel | A Award deriv | 2023-03-01 | 2023-03-03 | 85,000 | — | $0 | 85,000 | SEC↗ |
| Booth Bruce | Director | A Award deriv | 2023-03-01 | 2023-03-03 | 9,713 | $7.62 | $74.0K | 9,713 | SEC↗ |
| Bruhn Suzanne Louise | Director | A Award deriv | 2023-03-01 | 2023-03-03 | 6,235 | $7.62 | $47.5K | 6,235 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | A Award deriv | 2023-03-01 | 2023-03-03 | 370,000 | — | $0 | 370,000 | SEC↗ |
| Gray David L. F. | Chief Science Officer | A Award deriv | 2023-02-27 | 2023-02-27 | 267,000 | — | $0 | 267,000 | SEC↗ |
| Papapetropoulos Spyros | Chief Medical Officer | M Exercise deriv | 2022-11-18 | 2022-11-22 | 300 | — | $0 | 149,604 | SEC↗ |
| Papapetropoulos Spyros | Chief Medical Officer | M Exercise | 2022-11-18 | 2022-11-22 | 300 | $1.89 | $567 | 4,300 | SEC↗ |
| Papapetropoulos Spyros | Chief Medical Officer | S Sale | 2022-11-18 | 2022-11-22 | 300 | $14.00 | $4.2K | 4,000 | SEC↗ |
| Bruhn Suzanne Louise | Director | A Award deriv | 2022-07-27 | 2022-07-28 | 24,310 | — | $0 | 24,310 | SEC↗ |
| Thistle Mary | Director | A Award deriv | 2022-06-09 | 2022-06-13 | 12,155 | — | $0 | 12,155 | SEC↗ |
| Blanchard Cheryl R | Director | A Award deriv | 2022-06-09 | 2022-06-13 | 12,155 | — | $0 | 12,155 | SEC↗ |
| Vitorovic Stefan | Director | A Award deriv | 2022-06-09 | 2022-06-13 | 12,155 | — | $0 | 12,155 | SEC↗ |
| Booth Bruce | Director | A Award deriv | 2022-06-09 | 2022-06-13 | 12,155 | — | $0 | 12,155 | SEC↗ |
| Koenig Gerhard | Director | A Award deriv | 2022-06-09 | 2022-06-13 | 12,155 | — | $0 | 12,155 | SEC↗ |
| Thorp Clay | Director | P Buy | 2022-05-17 | 2022-05-17 | 14,893 | $2.97 | $44.2K | 1,556,030 | SEC↗ |
| Thorp Clay | Director | P Buy | 2022-05-16 | 2022-05-17 | 21,802 | $2.76 | $60.2K | 1,541,137 | SEC↗ |
| Thackaberry Evan | SVP, Head of Early Developme | P Buy | 2022-05-05 | 2022-05-06 | 1,500 | $4.00 | $6.0K | 1,500 | SEC↗ |
| Papapetropoulos Spyros | Chief Medical Officer | P Buy | 2022-05-03 | 2022-05-04 | 4,000 | $3.40 | $13.6K | 4,000 | SEC↗ |
| Ziolkowski Jennifer Lynn | Chief Financial Officer | P Buy | 2022-05-03 | 2022-05-04 | 4,000 | $3.77 | $15.1K | 4,000 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | P Buy | 2022-05-03 | 2022-05-04 | 1,000 | $3.94 | $3.9K | 203,687 | SEC↗ |
| Verni Christopher | General Counsel | P Buy | 2022-05-03 | 2022-05-04 | 4,000 | $3.77 | $15.1K | 4,000 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | P Buy | 2022-05-02 | 2022-05-04 | 4,000 | $3.61 | $14.4K | 202,687 | SEC↗ |
| Verni Christopher | General Counsel | A Award deriv | 2022-04-19 | 2022-04-20 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Thistle Mary | Director | A Award deriv | 2022-04-18 | 2022-04-20 | 24,309 | — | $0 | 24,309 | SEC↗ |
| Thorp Clay | Director | P Buy | 2022-03-28 | 2022-03-28 | 3,000 | $7.20 | $21.6K | 3,000 | SEC↗ |
| Ziolkowski Jennifer Lynn | Chief Financial Officer | A Award deriv | 2022-03-01 | 2022-03-03 | 110,000 | — | $0 | 110,000 | SEC↗ |
| Thackaberry Evan | SVP, Head of Early Developme | A Award deriv | 2022-03-01 | 2022-03-03 | 45,000 | — | $0 | 45,000 | SEC↗ |
| Papapetropoulos Spyridon | Chief Medical Officer | A Award deriv | 2022-03-01 | 2022-03-03 | 75,500 | — | $0 | 75,500 | SEC↗ |
| Blanchard Cheryl R | Director | A Award deriv | 2022-03-01 | 2022-03-03 | 5,017 | $9.63 | $48.3K | 5,017 | SEC↗ |
| Booth Bruce | Director | A Award deriv | 2022-03-01 | 2022-03-03 | 7,577 | $9.63 | $73.0K | 7,577 | SEC↗ |
| Magovcevic-Liebisch Ivana | President and CEO | A Award deriv | 2022-03-01 | 2022-03-03 | 282,000 | — | $0 | 282,000 | SEC↗ |
| Koenig Gerhard | Director | A Award deriv | 2022-03-01 | 2022-03-03 | 4,351 | $9.63 | $41.9K | 4,351 | SEC↗ |
| Alexandria Venture Investments | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-11 | 142,539 | — | $0 | 0 | SEC↗ |
| Alexandria Venture Investments | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-11 | 392,618 | — | $0 | 0 | SEC↗ |
| Northpond Ventures, LP | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-11 | 2,831,520 | — | $0 | 0 | SEC↗ |
| Northpond Ventures, LP | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-11 | 1,027,978 | — | $0 | 0 | SEC↗ |
| Vitorovic Stefan | Director | C Conversion deriv | 2022-01-11 | 2022-01-11 | 21,310 | — | $0 | 0 | SEC↗ |
| Vitorovic Stefan | Director | C Conversion deriv | 2022-01-11 | 2022-01-11 | 9,243,756 | — | $0 | 0 | SEC↗ |
| Booth Bruce | Director | C Conversion deriv | 2022-01-11 | 2022-01-11 | 7,852,374 | — | $0 | 0 | SEC↗ |
| Booth Bruce | Director | C Conversion deriv | 2022-01-11 | 2022-01-11 | 2,850,789 | — | $0 | 0 | SEC↗ |
| Atlas Venture Opportunity Fund | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-11 | 2,850,789 | — | $0 | 0 | SEC↗ |
| Atlas Venture Opportunity Fund | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-11 | 7,852,374 | — | $0 | 0 | SEC↗ |
| Vida Ventures GP III, L.L.C. | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-11 | 21,310 | — | $0 | 0 | SEC↗ |
| Vida Ventures GP III, L.L.C. | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-11 | 9,243,756 | — | $0 | 0 | SEC↗ |
| Thorp Clay | Director | C Conversion deriv | 2022-01-11 | 2022-01-11 | 2,552,021 | — | $0 | 0 | SEC↗ |
| Thorp Clay | Director | C Conversion deriv | 2022-01-11 | 2022-01-11 | 926,506 | — | $0 | 0 | SEC↗ |
| AMGEN INC | 10% Owner | C Conversion deriv | 2022-01-11 | 2022-01-11 | 3,206,281 | — | $0 | 0 | SEC↗ |
| Cormorant Global Healthcare Ma | Other | C Conversion deriv | 2022-01-11 | 2022-01-13 | 616,786 | — | $0 | 0 | SEC↗ |
| Alexandria Venture Investments | 10% Owner | C Conversion | 2022-01-11 | 2022-01-11 | 192,973 | — | $0 | 192,973 | SEC↗ |
| Northpond Ventures, LP | 10% Owner | C Conversion | 2022-01-11 | 2022-01-11 | 2,831,520 | — | $0 | 2,831,520 | SEC↗ |
| Northpond Ventures, LP | 10% Owner | C Conversion | 2022-01-11 | 2022-01-11 | 1,027,978 | — | $0 | 1,027,978 | SEC↗ |
| Northpond Ventures, LP | 10% Owner | P Buy | 2022-01-11 | 2022-01-11 | 355,000 | $14.00 | $4.97M | 1,382,978 | SEC↗ |
| Vitorovic Stefan | Director | P Buy | 2022-01-11 | 2022-01-11 | 1,671,148 | $14.00 | $23.40M | 5,004,393 | SEC↗ |
| Vitorovic Stefan | Director | C Conversion | 2022-01-11 | 2022-01-11 | 3,333,245 | — | $0 | 3,333,245 | SEC↗ |
| Vitorovic Stefan | Director | C Conversion | 2022-01-11 | 2022-01-11 | 7,684 | — | $0 | 7,684 | SEC↗ |
| Vitorovic Stefan | Director | P Buy | 2022-01-11 | 2022-01-11 | 3,852 | $14.00 | $53.9K | 11,536 | SEC↗ |
| Booth Bruce | Director | P Buy | 2022-01-11 | 2022-01-11 | 535,000 | $14.00 | $7.49M | 4,808,896 | SEC↗ |
| Booth Bruce | Director | C Conversion | 2022-01-11 | 2022-01-11 | 2,831,520 | — | $0 | 4,273,896 | SEC↗ |
| Booth Bruce | Director | C Conversion | 2022-01-11 | 2022-01-11 | 1,027,978 | — | $0 | 1,027,978 | SEC↗ |
| Atlas Venture Opportunity Fund | 10% Owner | C Conversion | 2022-01-11 | 2022-01-11 | 1,027,978 | — | $0 | 1,027,978 | SEC↗ |
| Atlas Venture Opportunity Fund | 10% Owner | P Buy | 2022-01-11 | 2022-01-11 | 535,000 | $14.00 | $7.49M | 4,808,896 | SEC↗ |
| Atlas Venture Opportunity Fund | 10% Owner | C Conversion | 2022-01-11 | 2022-01-11 | 2,831,520 | — | $0 | 4,273,896 | SEC↗ |
| Vida Ventures GP III, L.L.C. | 10% Owner | P Buy | 2022-01-11 | 2022-01-11 | 1,671,148 | $14.00 | $23.40M | 5,004,393 | SEC↗ |
| Vida Ventures GP III, L.L.C. | 10% Owner | C Conversion | 2022-01-11 | 2022-01-11 | 3,333,245 | — | $0 | 3,333,245 | SEC↗ |
| Vida Ventures GP III, L.L.C. | 10% Owner | P Buy | 2022-01-11 | 2022-01-11 | 3,852 | $14.00 | $53.9K | 11,536 | SEC↗ |
| Vida Ventures GP III, L.L.C. | 10% Owner | C Conversion | 2022-01-11 | 2022-01-11 | 7,684 | — | $0 | 7,684 | SEC↗ |
| Thorp Clay | Director | P Buy | 2022-01-11 | 2022-01-11 | 265,000 | $14.00 | $3.71M | 1,519,335 | SEC↗ |
| Thorp Clay | Director | C Conversion | 2022-01-11 | 2022-01-11 | 1,254,335 | — | $0 | 1,254,335 | SEC↗ |
| AMGEN INC | 10% Owner | C Conversion | 2022-01-11 | 2022-01-11 | 3,206,281 | — | $0 | 3,206,281 | SEC↗ |
| Cormorant Global Healthcare Ma | Other | C Conversion | 2022-01-11 | 2022-01-13 | 616,786 | — | $0 | 616,786 | SEC↗ |